Evens R

Department of Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

15 papers · 1 preprint · ORCID

ArticlePsychedelics

Personality changes following first-time psychedelic use in college students in Germany.

Volkmann C, Seitz M, Evens R +3

Europe PMC2026
ArticlePsilocybin

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

Europe PMC2026
ArticlePsilocybin

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Mertens LJ, Koslowski M, Betzler F +23

Europe PMC2026
ArticlePsychedelics

Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study.

Evens R, Uyar A, Gosslau E +4

Europe PMC2026
ArticlePsychedelics

Flashbacks Through Time: Historical Development and Current Use of the Term "Flashback" in Psychedelic and Post-Traumatic Stress Disorder Research.

Evens R

Europe PMC2026
ArticlePsilocybin

Classifying Psychedelic-Related Complications.

Majić T, Gouzoulis-Mayfrank E, Evens R

Europe PMC2026
ArticlePsychedelics

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Evens R, Uyar A, Majić T

Europe PMC2026
ArticlePsilocybin

Landscape analysis of pre-registered clinical trials involving classical psychedelics.

Uyar A, Forbrich L, Lueken U +1

Europe PMC2026
ArticlePsilocybin

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.

Majić T, Schmidt TT, Gröticke A +4

Europe PMC2025
PreprintPsilocybin

The Afterglow Inventory (AGI) – validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics

Majic T, Schmidt TT, Gröticke A +4

Europe PMC2024
ArticlePsychedelics

Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).

Wolff M, Evens R, Mertens LJ +6

Europe PMC2024
ArticlePsilocybin

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.

Evens R, Schmidt ME, Majić T +1

Europe PMC2023
ArticlePsilocybin

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.

Mertens LJ, Koslowski M, Betzler F +9

Europe PMC2022
ArticlePsilocybin

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.

Wolff M, Mertens LJ, Walter M +2

Europe PMC2022
ArticlePsychedelics

Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.

Evens R, Reiche S, Marek RM +9

Europe PMC2021
ArticlePsilocybin

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance.

Wolff M, Evens R, Mertens LJ +4

Europe PMC2020